Q4 25 EPS
$4.47
BEAT +1.59%
Est. $4.40
Q4 25 Revenue
$7.17B
BEAT +0.98%
Est. $7.10B
vs S&P Since Q4 25
-23.0%
TRAILING MARKET
SYK -18.8% vs S&P +4.1%
Full Year 2025 Results
FY 25 EPS
$13.63
BEAT +0.53%
Est. $13.56
FY 25 Revenue
$25.12B
BEAT +0.28%
Est. $25.05B
Market Reaction
Did SYK Beat Earnings? Q4 2025 Results
Stryker closed out fiscal 2025 on a strong note, delivering a fourth-quarter beat on both the top and bottom lines as the medical device giant crossed a milestone $25 billion in annual revenue for the first time. Adjusted EPS of $4.47 edged past the … Read more Stryker closed out fiscal 2025 on a strong note, delivering a fourth-quarter beat on both the top and bottom lines as the medical device giant crossed a milestone $25 billion in annual revenue for the first time. Adjusted EPS of $4.47 edged past the $4.40 consensus estimate by 1.59%, while revenue of $7.17 billion topped expectations by 0.98% and grew 11.4% year-over-year, driven in large part by the MedSurg and Neurotechnology segment, which posted 17.5% reported growth to $4.56 billion, with Vascular sales surging 58.1% on the strength of the Inari Medical acquisition completed earlier in the year. Adjusted operating income margin expanded 100 basis points to 30.2%, marking the second straight year of at least that level of margin improvement. The company's limited market release of its Mako RPS handheld robotic system adds a promising new dimension to its orthopedic robotics portfolio heading into 2026, when management expects organic net sales growth of 8.0% to 9.5% and adjusted diluted EPS of $14.90 to $15.10.
Key Takeaways
- • Organic net sales growth of 11.0% in Q4 driven by 10.9% increased unit volume and 0.1% higher prices
- • MedSurg and Neurotechnology organic sales growth of 12.6% in Q4
- • Orthopaedics organic sales growth of 8.4% in Q4
- • Vascular segment Q4 sales surged 58.1% driven by the Inari Medical acquisition
- • Adjusted operating margin expanded 100 bps to 30.2% in Q4
- • Strong procedural volumes and capital product demand
SYK YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
SYK Revenue by Segment
With YoY comparisons, source: SEC Filings
SYK Revenue by Geography
With YoY comparisons, source: SEC Filings
“We had an outstanding finish to 2025, driving double-digit sales and adjusted earnings per share growth for the fourth quarter and full year while delivering adjusted operating margin expansion of at least 100 basis points for the second consecutive year.”
— Kevin A. Lobo, Q4 2025 Earnings Press Release
SYK Earnings Trends
SYK vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
SYK EPS Trend
Earnings per share: estimate vs actual
SYK Revenue Trend
Quarterly revenue: estimate vs actual
SYK Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.60 | — | $6.02B | -4.89% |
| Q4 25 BEAT FY | $4.40 | $4.47 | +1.59% | $7.17B | +0.98% |
| FY Full Year | $13.56 | $13.63 | +0.53% | $25.12B | +0.28% |
| Q3 25 BEAT | $3.13 | $3.19 | +1.86% | $6.06B | +0.20% |
| Q2 25 BEAT | $3.07 | $3.13 | +1.94% | $6.02B | +1.57% |
| Q1 25 BEAT | $2.73 | $2.84 | +4.03% | $5.87B | +3.07% |